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Abstract
Head and neck squamous carcinoma (HNSCC) tumors carry dismal long-term prognosis and the role of tumor initiating cells
(TICs) in this cancer is unclear. We investigated in HNSCC xenografts whether specific tumor subpopulations contributed to
tumor growth. We used a CFSE-based label retentions assay, CD49f (a6-integrin) surface levels and aldehyde dehydrogenase
(ALDH) activity to profile HNSCC subpopulations. The tumorigenic potential of marker-positive and -negative
subpopulations was tested in nude (Balb/c nu/nu) and NSG (NOD.Cg-Prkdc
scid Il2rg
tm1Wjl/SzJ) mice and chicken embryo
chorioallantoic membrane (CAM) assays. Here we identified in HEp3, SQ20b and FaDu HNSCC xenografts a subpopulation of
G0/G1-arrested slow-cycling CD49f
high/ALDH1A1
high/H3K4/K27me3
low subpopulation (CD49f+) of tumor cells. A strikingly
similar CD49f
high/H3K27me3
low subpopulation is also present in primary human HNSCC tumors and metastases. While only
sorted CD49f
high/ALDH
high, label retaining cells (LRC) proliferated immediately in vivo, with time the CD49f
low/ALDH
low,
non-LRC (NLRC) tumor cell subpopulations were also able to regain tumorigenic capacity; this was linked to restoration of
CD49f
high/ALDH
high, label retaining cells. In addition, CD49f is required for HEp3 cell tumorigenicity and to maintain low
levels of H3K4/K27me3. CD49f+ cells also displayed reduced expression of the histone-lysine N-methyltransferase EZH2 and
ERK1/2phosphorylation. This suggests that although transiently quiescent, their unique chromatin structure is poised for
rapid transcriptional activation. CD49f2 cells can ‘‘reprogram’’ and also achieve this state eventually. We propose that in
HNSCC tumors, epigenetic mechanisms likely driven by CD49f signaling dynamically regulate HNSCC xenograft phenotypic
heterogeneity. This allows multiple tumor cell subpopulations to drive tumor growth suggesting that their dynamic nature
renders them a ‘‘moving target’’ and their eradication might require more persistent strategies.
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Introduction
Head and neck squamous cell carcinoma (HNSCC) is an
aggressive disease for which treatment has improved little over the
last three decades. A complicating factor is that despite the
discovery of certain genetic alterations and an HPV+ subgroup of
tumors, the genetics and cell biology of this cancer is heteroge-
neous and poorly characterized, while the epigenome remains an
enigma [1,2]. A critical, but only recently explored question is the
existence and behavior of tumor subpopulations in HNSCC that
may or may not behave like tumor initiating cells (TICs).
HNSCC primary tumors have been shown by Prince et al. to
contain a subpopulation of CD44+/Lin2 cells, which correlated
with TIC potential [3]. CD44+ expression also correlated with
higher expression of Bmi1, a polycomb group PRC1 complex
component that controls self-renewal [4]. Recently this same
group demonstrated that the CD44+ population overlaps with an
aldehyde dehydrogenase ALDH1A1
high subpopulation that dis-
played enhanced tumorigenicity [5]. Hierarchical or non-hierar-
chical models are proposed to explain the behavior of marker-
defined tumor cell subpopulations. The first, proposes that the
TIC compartment is a distinct minority and that these cells have
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e29974the ability to self-renew as well as produce identifiable progenitor,
transit amplifying or differentiated cells [6,7]. The non-hierarchi-
cal model proposes that TICs result from the random occurrence
of TIC-specific or other (e.g., clonally selected) properties and any
cell in the tumor can be a TIC [8,9,10,11,12]. The data on the
existence and functionality of TICs for different human malig-
nancies is conflicting. For example, in human melanoma marker
defined subpopulations of tumor cells have been shown to be
responsible for tumor initiation and growth [13,14,15]. However,
other studies showed that tumor expansion in this malignancy (as
well as in colon carcinoma or mouse leukemias) was propelled by
genetically distinct clones or by operationally defined TICs that
occurred at high frequency [8,9,11,16]. Importantly, it is now
clear that this apparent discrepancy between studies might arise
from the fact that the results are highly dependent on the culture
conditions, how tumors were enzymatically digested to produce
single cell suspensions [8,15] and the degree of immuno-deficiency
of the xenograft model used [9,13]. While there is strong support
for the existence of molecularly-defined TICs in certain tumors, it
is also possible that a dynamic regulation of ‘‘stem-cell properties’’
might explain models that seem to display a non-hierarchical
behavior [17,18]. This mechanism may provide transient
populations with a TIC potential that dynamically and reversibly
establish a hierarchical structure during tumor growth.
A growing number of experimental and theoretical studies
suggest that the TIC phenotype might be more dynamic than
expected [17,18]. These studies motivated us to explore whether a
dynamic behavior of discrete tumor cell subpopulations might
drive HNSCC tumor growth. Studies in the HEp3 HNSCC model
showed that in vivo serially transplanted tumors retain their
tumorigenicity and display .90% engraftment in Balb/c nude
mice or chick embryo systems (CAM) [19,20]. Further, when these
tumor cells were cloned at nearly 100% efficiency, so that primary
tumor heterogeneity was well represented, all clones (10
2), albeit
after different latency periods, were invariably tumorigenic and
transplantable [20]. These studies provided an initial hint that in
HNSCC and perhaps other tumors, a dynamic regulation of
tumor initiating properties drives tumorigenic potential.
Here we identify, in experimental models of HNSCC a tumor
cell subpopulation defined as transiently G1 arrested, CD49f
high/
ALDH1A1
high/P-ERK1/2
low/H3K27/K4me3
low cells (CD49f+)
with immediate enhanced engraftment capacity. This CD49f
high/
H3K27me3
low subpopulation was also found in specimens from
human primary tumors and metastases. Importantly, our data
revealed that these phenotypes are dynamic and even pure
CD49f
low (CD49f2) subpopulations can eventually give rise to
CD49f+ cells with tumorigenic potential. This associates with
specific changes in ERK1/2 activation, histone H3 post-
translational modifications and with changes in the expression of
CD49f (a6-integrin) and ALDH activity. Thus, we identify at least
two coexisting subpopulations in growing tumors that only differ in
the timing of their tumorigenicity rather than in their overall
potential. This work might reveal novel dynamics on how
phenotipically heterogeneous subpopulations of tumor cells
maintain solid tumor growth.
Results
ALDH1A1
High/CD49f
High Tumor Cells Define a Slow-
Dividing Subpopulation in HNSCC HEp3 tumors
High aldehyde dehydrogenase-ALDH1A1 activity (henceforth
ALDH)wasshown toidentify hematopoietic, breastand colon cancer
stemcells[21,22,23].WeexaminedthedistributionofALDHactivity
in HEp3 cells obtained from tumors grown on chicken embryo
chorioallantoic membrane (CAM) that provides a completely
immune-deficient environment where these tumor cells grow for
one week and can be weekly passaged [19,20,24] or nude mice
according to published methods [23]. HEp3 tumorigenicity in nude
mice and CAM system [19,25,26] as well as in NSG mice (this study)
are virtually indistinguishable. This analysis revealed that while the
majority of HEp3 cells had low ALDH activity, a subpopulation
comprising ,14% of the tumor is ALDH
high (14.2066.05%,
p=0.00006) and this activity is sensitive to DEAB (ALDH inhibitor)
(Fig. 1A). Detection of surface CD49f, a surface integrin (a6)
upregulated in HNSCC tumors and also a marker of normal stem
cells in various tissues [27,28,29,30], showed that freshly harvested
HEp3 cells from tumors or SQ20b and FaDu cells from culture
expressed high levels of this integrin (Fig. S1A). Moreover, ALDH
high
HEp3 cells obtained from CAM tumors express in average ,2f o l d
higher levels of surface CD49f than ALDH
low HEp3 cells
(352761116 vs. 19086437, p=0.008) (Fig. 1B) and in some tumors
these differences reached a maximum of 4 fold (Fig. 1B). In
agreement with previous studies [31,32], we also found that
ALDH
high HEp3 cells displayed slightly higher levels of surface
CD44 when compared to ALDH
low HEp3 cells (1.3 folds higher,
17936345 vs. 13316233, p=0.0026) (Fig. S1B). ALDH
high HEp3
cells were negative or showed no difference from the ALDH
low
counterpart for other defined markers such as CD71 (63546979 vs.
530761217, p=0.52) (Fig. S1C), CD34 [33,34], CD200 [33] and
CD133 [35] (data not shown). We conclude that HNSCC HEp3
tumors contain a sub-population of ALDH
high/CD49f
high cells.
TICs such as leukemic stem cells are proposed to retain stem
cell-like properties, such as quiescence [36]. Therefore, we
analyzed the cell cycle distribution of ALDH
high/CD49f
high vs.
ALDH
low/CD49f
low cells in freshly harvested HEp3 tumors by
combining detection of ALDH activity, CD49f expression and
DNA content and viability using Hoechst (Fig. 1C – triple stain).
In contrast to ALDH
low/CD49f
low HEp3 cells that showed a cell
cycle distribution consistent with active cycling (7668% G0/G1,
18.3665.9% S+G2/M), ALDH
high/CD49f
high HEp3 cells were
found mainly in G1 and very few cells were found in G2+M phases
(90.463.9% G0/G1, 8.665.4% S+G2/M) (Fig. 1C). This suggests
a slow cycling behavior for the ALDH
high/CD49f
high cells.
Consistent with previous results [37] the percentage of sub-G0
apoptotic cells was low, ranging 2–6% in HEp3 tumors (not
shown). We conclude that ALDH
high/CD49f
high cells are
primarily in a G1-arrest, while ALDH
low/CD49f
low cells in the
tumor mass show a profile consistent with active expansion.
Label Retaining Cells are Enriched for CD49f in HEp3
primary Tumors
The G1 arrest observed in ALDH
high/CD49f
high cells motivat-
ed us to use a functional approach to search for slow cycling cells
using a label retaining assay using the vital green-fluorescent dye
CFSE (Fig. 2A) [38]. CFSE label retention provides a functional
assay for a phenotype associated with normal stem cell behavior
(i.e. quiescence) and also it provided a functional and unbiased
method for which we could then test overlap with the molecularly
defined populations. T-HEp3 cells from freshly harvested tumors
were loaded with CFSE (20 mM) for 20 min, washed and injected
in nude mice or CAMs. CFSE had no effect on cell viability or
proliferation rates (not shown). Detection of CFSE+ HEp3 cells in
cytospins within one week of CAM tumor growth (day 4 shown)
revealed a small fraction of LRCs (Fig. 2A lower panel). After
collagenase-I mediated digestion of tumors and FACS analysis to
detect the CFSE+ population we found that tumor cells displayed
varying degrees of CFSE signal consistent with the number of
divisions (Fig. 2A and Fig. S1D). FACS analysis revealed that label
Phenotypic Heterogeneity of HNSCC Subpopulations
PLoS ONE | www.plosone.org 2 January 2012 | Volume 7 | Issue 1 | e29974Figure 1. T-HEp3 Cells Contain an ALDH1A1
high, CD49f
high and CD44
high Cell Sub-population. (A) FACS analysis of ALDH1A1 activity in T-
HEp3 tumors grown in nude mice. Left- Representative Histogram of ALDH1A1 expression. Percentages=frequency of ALDH
high cells. Right-
quantification of the percentage of ALDH1A1
high cells in at least 3 different HEp3 tumors. (B) FACS analysis of CD49f expression in the ALDH
high and
ALDH
low subpopulations. Left - representative histograms, with numbers indicating the CD49f mean fluorescence intensity (MFI). Right -
quantification of CD49f MFI in at least 3 different HEp3 tumors. (C) HEp3 tumor cells stained for ALDH1A1 activity, CD49f and Hoechst were FACS
analyzed for cell cycle profile. Cell cycle profile (left) and quantification (right). Percentage of cells was calculated using BD FACSDiva software,
excluding cell doublets and aggregates. Columns - mean of three independent experiments. The numbers represent the percentage of cells on G0-
G1phase. p-values estimated using Mann-Whitney non-parametric test.
doi:10.1371/journal.pone.0029974.g001
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CAMs (4 days). This proportion is further decreased by day 7 in
CAM tumors (Fig. 2B) and it represents 6% of the tumor cell
population in nude mice-grown HEp3 tumors for 7–8 days. This
proportion also decreases by day 12 in nude mice (Fig. 2B). In fact,
the CFSE-marked LRCs were no longer detectable after 2 weeks
in vivo in either system CAM or nude mice, indicating that all
LRCs divided enough times to completely dilute the label.
However, if the cells derived from these tumors that had diluted
the label were relabeled with CFSE and reinoculated in vivo,a
LRC subpopulation was again obtained after one week of in vivo
growth. This suggests that although all LRCs eventually dilute the
label (i.e. cycle) this population is regenerated. Propidium iodide or
Hoechst labeling indicated that CFSE retaining cells are viable
(data not shown).
In order to determine whether the CD49f
high cells partitioned
preferentially to the quiescent label retaining tumor cell population
or whether these methods identified distinct populations, CFSE
high
cells were used to detect CD49f surface expression through
immunofluorescence (IF) and FACS. Detection of CD49f was
performed in HEp3 LRCs and non-LRCs (NLRCs) obtained from
6 days old CAM tumors. As shown in figure 2C close to 80% of all
HEp3 LRCs are CD49f
high (Fig. 2C and Fig. S1E). The CD49f
signal was cytoplasmic and membranous because cells were
permeabilized revealing integrins in the ER and Golgi. This
method allows only scoring positive vs. negative cells using a
threshold of signal detection by the microscope camera. To further
quantify these differences we measured CD49f expression by FACS
(surface CD49f) and found that HEp3 LRCs (CFSE+) express 3.5
fold more surface CD49f (mean fluorescence intensity) than NLRCs
(Fig. 2D). This strongly suggests that the LRC/CD49f
high sub-
population overlaps with the ALDH
high/CD49f
high sub-population
that shows the highest degree of CD49f expression (Fig. 1B, 2D).
CFSE labeling of SQ20b cells and injection in nude mice
revealed after 7–14 days in vivo the presence of a slow-cycling LRC
population that represented 1.560.7% of tumor cells (Fig. S1F).
Quantification of CD49f expression by FACS in LRCs and
NLRCs from SQ20b and FaDu tumors grown in nude mice
showed that the LRCs population expressed statistically significant
higher levels of CD49f (Fig. 2E and 2F) (SQ20b: 972.66150.8 vs.
551.66172.1, p,0.0001. FaDu: 1752.6692.8 vs. 261.664.0,
p,0.0001). Collectively, these data suggests that in tumors
produced by at least three different HNSCC cell lines (one serially
maintained in vivo – HEp3) a subpopulation of CD49f
high cells
appears to be transiently growth arrested.
A CD49f
high Sub-population is Present in Primary tumors
and Metastasis from HNSCC patients
CD49f has been identified as a normal stem cell marker and
overall expression of CD49f is increased in human HNSCC
tumors [27,28,30,39,40]. Thus, we tested in sections from human
HNSCC primary tumors and metastasis whether a CD49f
high cell
subpopulation was also present. Staining with the anti-CD49f
antibody showed that CD49f expression was higher in the basal
layer of cells of the adjacent mucosa (Fig. S2A). CD49f staining
decreased in the suprabasal more differentiated cell layers.
Examination of 9 primary tumors and 8 matching lymph node
metastases using IHC or immunofluorescence (Fig. 3A–F)
(representative of poorly differentiated squamous cell carcinoma
with high sarcomatoid differentiation) revealed that CD49f
expression in these tumors was limited to subpopulations
representing 5–18% (Fig. 3) of all tumor cells. The very strongly
stained CD49f cells that showed a characteristic membrane and
cytoplasmic staining were interspersed in the tumor mass (Fig. 3).
The proportion of this subpopulation was similar to that detected
in HEp3 tumors using FACS, IF (Fig. 2) and immunohistochem-
istry (IHC) (Fig. S2B). The frequency of CD49f
high cells
significantly increased in 75% (6/8) patient metastases (12–30%)
(Fig. 3G and Fig. S2C) compared to primary lesions and this was
accompanied by increased staining intensity (Fig. 3B and D).
Thus, a CD49f
high cell subpopulation detected in HNSCC cell
lines is present in aggressive tumors and enriched in lymph node
metastases from HNSCC patients. This suggests that the
CD49f
high population studied in the experimental systems might
be informative of this CD49f
high population found in tumor
samples obtained from patients.
Both ALDH
High/CD49f
High Cells and LRCs Display
Enhanced Proliferative Potential In Vivo
We next examined whether the ALDH
high/CD49f
high, LRC or
CD49f
high sub-populations differed in their proliferative capacity
in vivo from those that had lower levels of these markers. We sorted
the T-HEp3 cells from nude mouse parental tumors into those
with high or low CD49f levels (Fig. 4A, C and E) and/or ALDH
activity (Fig. 4A, E and Fig. S3A). Proliferative capacity was
monitored in the immunodeficient CAM model where HEp3 cells
display high engrafting efficiency. This is a convenient way to
monitor for proliferative capacity within 1 week [19,20,24]. Viable
sorted HEp3 cells were inoculated at 10
2–10
3–10
4 cells/CAM
(20–2000 fold fewer cells than conventionally used [19,41,42]. We
found that in all cases only CD49f
high (Fig. 4C), ALDH
high (Fig.
S3A) or ALDH
high/CD49f
high (Fig. 4 E–G) HEp3 cells displayed
efficient proliferative potential in vivo, a difference detected with as
little as 100 cells, meanwhile CD49f
low (Fig. 4C), ALDH
low (Fig.
S3A) or ALDH
low/CD49f
low (Fig. 4 E–G) HEp3 cells were
inefficient in their ability to grow. Lack of growth of CD49f
low,
ALDH
low/CD49f
low HEp3 cells was not due to dilution by host
cells or due to effects of collagenase treatment on surface CD49f
expression (Fig. S3B and data not shown). In addition, this
difference was not attributable to differences in the adhesive
Figure 2. CD49f
high Cells Are A Slow Cycling Population in T-HEp3 Tumors. (A) Upper panel, strategy to use CFSE (20 mM) to identify LRCs
in HEp3 tumors in vivo. CFSE diffuses into the cells and is esterified onto proteins. Cell division dilutes the label and the slow-cycling or growth
arrested cells will retain the CFSE (label retaining cells - LRCs). Lower photograph - cytospin from a CFSE-labeled 4 day T-HEp3 tumor grown on the
CAM. The LRCs (green cells, arrows) can be easily identified. Scale bar: 80 mm and 40 mm inset scale bar. (B) FACS detection and quantification of the
CFSE population after in vivo growth. Upper panel - dot-plot graph of unstained (UN) T-HEp3 tumors; middle panel - CFSE labeled tumors after 7 days
(d7) in vivo. Lower panel - percentage of LRCs determined by fluorescence microscopy in HEp3 (T) tumors grown on CAMs or nude mice d4–d12 after
injection. Top numbers=mean percent of LRCs per tumor. (C) Detection of CD49f in LRCs and NLRCs in d6 CAM tumors by IF. LRCs (green) are
positive for CD49f (red), arrows. Inset, merged image of CD49f and CFSE signals. CFSE signal bathes the whole cell but primarily the cytosol. CD49f
signal in permeabilized HEp3 cells excluded completely the nucleus (Blue, DAPI). Scale bar: 60 mm and 40 mm inset scale bar. Lower panel graphs -
quantification of CD49f
high cells in both LRC and NLRC populations. (D) Quantification of surface CD49f
high cells in both LRC and NLRC populations
by FACS. p-values estimated using Mann-Whitney non-parametric test. (E–F) FACS quantification of CD49f expression in LRCs and NLRCs in SQ20b (E)
and FaDu (F) tumors grown in nude mice. Statistical significance was estimated using Mann-Whitney non-parametric test and 95% confidence
interval.
doi:10.1371/journal.pone.0029974.g002
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PLoS ONE | www.plosone.org 5 January 2012 | Volume 7 | Issue 1 | e29974Figure 3. Primary tumors and metastasis from HNSCC patients contain a subpopulation of CD49f
high cells. (A–D) Representative CD49f
staining in primary tumors (A and C) and lymph node metastasis (B and D) from two different patients. CD49f
high tumor cells are marked with arrows.
Note the strong cytosolic and membrane pattern of the signal (arrowhead in the, inset) and the overall stronger signal and increased frequency for
CD49f in the metastatic lesions (B and D). Scale bar: 80 mm and 40 mm inset scale bar. (E–F) Immunofluorescence detection of CD49f in sections from
human oral primary tumors (E) and metastasis (F) (PT68880). Scale bar: 60 mm. (G) Quantification of CD49f
high cells in sections from primary tumors
and lymph node metastasis. Columns represent mean of 5 different sections per sample and a minimum of 500 cells was scored per sample. p-values
estimated using one-way ANOVA followed by the Bonferroni correction with two-tailed P values,0.05 considered significant.
doi:10.1371/journal.pone.0029974.g003
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high and CD49f
low cells to fibronectin, collagen-I
or laminin-I (Fig. S3C). This was paralleled by equal adhesion of
CD49f
high and CD49f
low cells to the CAM tissue as 24 hrs after
inoculation, there was no difference in the number of tumor cells
recovered from the tissues (Fig. 4F). Thus, the enhanced
proliferative capacity does not results from an enhanced adhesive
potential due to CD49f enrichment that simply allows more cells
to survive the in vivo inoculation.
We also sorted HEp3 LRCs from NLRCs using CFSE label
retention after one week in nude mice (Fig. 4B). These were
inoculated at 10
3 or 10
4 cells/CAMs (Fig. 4D and G) or at 10
3
cells/mouse in nude mice (Fig. 5A) with Matrigel. HEp3 LRCs
inoculated in CAM were more efficient in proliferating in vivo
(Fig. 4D) and similar to the tumor nodules produced by
ALDH
high/CD49f
high, HEp3 LRCs also produced solid tumor
nodules (Fig. 4G). In agreement with this, HEp3 LRCs injected in
nude mice showed a faster tumor take and thus shorter latency
phase than their NLRCs counterparts (Fig. 5A, left graph). When
monitoring the populations of cells that did not grow (HEp3
marker-low or NLRCs) we found that regardless of the label used
for sorting (ALDH, CD49f or CFSE) these surviving cells did
not divide efficiently during the first week: non-tumorigenic
(ALDH
low/CD49f
low or NLRCs) 0.360.1 vs. tumorigenic
(ALDH
high/CD49f
high or LRCs) 0.8660.1 population dou-
blings/day (p,0.0001 t-test two tailed). We conclude that using
three independent markers, we can identify an ALDH
high/
CD49f
high slow-cycling population in T-HEp3 tumors. These
cells are endowed with proliferative capacity such that when
sorted, they are capable of a rapid exit from their transient growth
arrest, a strong and immediate proliferative response not observed
in the marker
low (ALDH
low/CD49f
low) or NLRC subpopulation.
CD49f
low cells or NLRCs Display a Latent Tumorigenic
Potential
We next tested the in vivo long-term stability of the phenotype
associated with ALDH
high/CD49f
high or LRCs and ALDH
low/
CD49f
low or NLRCs subpopulations. If ALDH
high/CD49f
high
cells or LRCs are the only ones endowed with tumorigenic
capacity these should be the only population showing transplant-
ability in vivo. As shown above in the first week in vivo CD49f
high/
LRC cells sorted from nude mice tumors proliferated more
efficiently than CD49f
low/NLRC cells in vivo (Fig. 4C–D).
However, upon serial transplantation in CAM we observed that
by week 3, CD49f
low HEp3 cells had regained growth capacity
(Fig. 5B). A similar behavior was observed for HEp3 NLRCs, by
week 5 they had recovered their tumorigenic capacity (Fig. S4A).
Likewise, when we injected 10
3 HEp3 LRCs or NLRCs in nude
mice, while LRCs had a shorter latency than NLRCs, we observed
no difference in overall tumor take, indicating that tumorigenic
potential is similar for HEp3 LRCs and NLRCs (Fig. 5A right and
left panels). A similar behavior was observed for SQ20b LRCs and
NLRCs sorted cells and injected in NSG mice (Fig. 5C). Thus,
during the first 15–20 days, NLRCs, isolated from either HEp3 or
SQ20b tumors and inoculated in mice or CAMs, show only a
transient delay in exponential growth initiation but this does not
impact their overall tumor take (Fig. 5A, B and C).
The restoration of tumorigenic potential was also observed after
in vitro expansion of the HEp3 LRC and NLRC sorted
subpopulations. All sorted subpopulations efficiently proliferated
in culture (Fig. S4B and data not shown) and upon injection, all
progenies from HEp3 LRCs and NLRCs were able to form
tumors with similar efficiency in nude mice (Fig. 5D) or on CAM
(Fig. S4C). Moreover, the ability of the progeny of NLRCs kept in
vitro to regain tumorigenic capacity in those first two weeks in vivo
was stable, as the tumors were able to grow again upon
transplantation (Fig. S4C). The same behavior was observed for
the progeny of the ALDH
high and ALDH
low HEp3 sorted
populations that were expanded in vitro and then inoculated on
CAM (Fig. S4D). To rule out the possibility that NLRCs were
contaminated with LRCs that escaped detection we performed
purity tests before and after sorting of the NLRC population (Fig.
S5A). We also used double detection during the sort to avoid
contaminating both fractions with cells that are non-specifically
attached to each other. Using these procedures and stringent gates
we found that the percent of positive cells in the negative fractions
was as follows for three different labels (ALDH 0.560.05; CFSE
0.5360.07; CD49f 0.560.25). However, because the sorted events
may not always represent live cells at these low levels we visually
inspected the sorted fractions via fluorescence microscopy. In all
cases the negative fraction was fully devoid of marker-positive cells
(data not shown). To further rule out that a contaminant of TICs
might be responsible for regained tumorigenecity of the marker-
negative cells, we calculated what would be the percent of the total
tumor cell number contributed by these contaminating cells in
weeks 1–3 for the CD49f (Fig. 5B) and weeks 1–7 for CFSE sorts
(Fig. S4A). Based on these calculations we found that in the CD49f
sort, CD49f
high cells contaminating the CD49f
low fraction would
only account for 0.2, 4.0 and 4.2% of cells in those tumors in
weeks 1, 2 and 3, respectively. In the CFSE sorts a similar result
was obtained and after the 4
th week of propagation only 2.4–3.0%
of the total tumor cells in the NLRC tumors would derive from
contaminating CFSE+ cells. Thus, our results strongly support that
the vast majority (95.8–99.5%) of the tumor growth produced by
CD49f
low and NLRCs is due to the marker-low/negative cells.
This further argues that although delayed in time marker-low/
negative cells can be tumorigenic. In addition, in two independent
sorts the progeny of HEp3 LRCs and NLRCs kept in culture
retained CD49f
high/ALDH
high and CD49f
low/ALDH
low expres-
sion/activity (Fig. 5E–F and Fig. S5B upper panels), even after 100
passages in vitro (Fig. S5C) suggesting they are highly pure and
stable (at least in vitro) marker
low populations. The same results
were obtained when CD49f mRNA expression was measured by
qPCR in HEp3 CD49f
high and CD49f
low progeny and in HEp3
LRC and NLRC progeny (Fig. S5D).
In stark contrast to the difference in marker levels observed in
vitro (Fig. 5E–F) and that resembled the original sort, all tumors
formed by HEp3 LRC and NLRC progeny displayed equal and
high levels of surface CD49f as well as ALDH (Fig. 5E–F, Fig. S5B
lower panels). In fact, HEp3 NLRC-derived tumors displayed
even higher ALDH levels than LRCs (Fig. 5F). Thus, even HEp3
NLRCs that can stably maintain a CD49f
low/ALDH
low profile in
culture (Fig. 5E–F), are able to reactivate into a tumorigenic
Figure 4. ALDH
high, CD49f
high, LRCs proliferative capacity in vivo. (A) Sorting strategy for HEp3 cells with high or low levels of ALDH, CD49f,
or both. (B) Sorting strategy for HEp3 tumors labeled with CFSE. (C–E) Quantification of tumor growth after 1 week in vivo on CAM. Dots represent
the number of tumor cells per nodule. CD49f
high vs. CD49f
low cells (C), LRC vs. NLRCs (D), and (E) ALDH
high/CD49f
high vs. ALDH
low/CD49f
low.( F)
Quantification of tumor growth after 24 h in vivo on CAM. Dots represent the number of tumor cells per nodule. (G) Representative images of tumor
nodules produced by ALDH
high/CD49f
high and ALDH
low/CD49f
low (left panel) or LRCs and NLRCs (right panel). T=tumor, H=host tissue (CAM),
I=inoculation site. Scale bar: 8 mm. p-values estimated using one-way ANOVA followed by the Bonferroni correction with two-tailed P values,0.05
considered significant.
doi:10.1371/journal.pone.0029974.g004
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with restoration of a CD49f
high/ALDH
high profile (Fig. 5E–F) and
regeneration of a LRC subpopulation (Fig. S5E). We conclude
that although upon sorting, CD49f
low/ALDH
low cells or NLRCs
display diminished proliferative capacity they are not terminally
committed to this phenotype. Instead these cells can regain
tumorigenic capacity and this is associated with restoration of a
CD49f
high and ALDH
high profile.
Furthermore, CD49f was required to support HEp3 tumor
growth because downregulation of CD49f using a siRNA or
blocking CD49f function with a function-blocking monoclonal
antibody (clone GoH3) caused a significant reduction in HEp3
tumor growth (Fig. 5G–5H). It is unlikely that, the GoH3 antibody
completely blocks adhesion of HEp3 cells to the ECM in vivo as
HEp3 cells adhere poorly to laminin when compared to a5b1-
integrin-mediated adhesion to fibronectin or adhesion to collagen-
I [41,43] (Fig. S3C). We conclude that CD49f activity in this
system is functionally linked to HEp3 tumorigenicity.
Phosphorylation of ERK
MAPK and Methylation of Histone-
3 (H3) Tail in Intratumor LRCs and NLRCs
Our data revealed a dynamic heterogeneity in the cycling
capacity of marker defined subpopulations in HNSCC experi-
mental tumors, a characteristic that seems associated with the
timing of tumorigenic capacity. These different behaviors might
have a functional role during tumor growth. Thus, we character-
ized how HNSCC cells transit into and out of the slow-cycling
CD49f
high phenotype. Using an Elk-GAL4::GFP reporter we
previously showed that ERK1/2 activity is high in growing HEp3
tumors, but not all HEp3 cells activated ERK [19], suggesting that
not all cells within the tumor were actively exiting G0–G1. Thus,
we explored the levels of ERK1/2 phosphorylation directly in
HEp3 LRCs in situ. Staining for CFSE and P-ERK1/2, revealed
that while ,70% of NLRCs showed strong P-ERK1/2 signal only
20% of the LRCs showed ERK1/2 activation (Fig. 6A upper
panel). Thus, the slow-cycling behavior of LRCs correlated with
reduced ERK1/2 activation. We next tested P-ERK1/2 levels in
HEp3 sorted LRCs, because immediately after sorting these P-
ERK1/2
low cells proliferate efficiently (Fig. 4D). Western blot for
P-ERK1/2 and total ERK1/2 levels revealed that the progeny of
LRCs actively proliferating in culture displayed stronger ERK1/2
phosphorylation than the progeny of NLRCs; total ERK1/2 levels
remained unchanged (Fig. 7A). In culture the proliferation of
LRCs and NLRCs was indistinguishable (data not shown),
suggesting that the main change is a burst in ERK1/2 activation
upon sorting of LRCs that were slow cycling or arrested in the
tumor. We conclude that in LRCs, the transient growth arrest and
low ERK1/2 phosphorylation are dynamically regulated and that
sorting relieves a break on ERK1/2 activity that correlates with
active proliferation.
The data above suggest that HEp3 LRCs are poised for
immediate expansion upon sorting (Fig. 4D) or within tumors in
response to an unidentified signal that activates their G0–G1 exit
in vivo. HEp3 NLRCs are also poised for growth (Fig. 5A–C), but
apparently must undergo a ‘‘reprogramming’’ phase that takes
longer (15–21 days) (Fig. 5 A–C). A similar scenario was reported
for embryonic stem cells that have their chromatin in a ‘‘bivalent’’
state that must be resolved upon receiving specific stimuli to
differentiate [44]. Recently, high levels of a histone 3 (H3) lysine-4
(H3K4) demethylase JARID1B were shown to define a slow-
cycling sub-population important for melanoma tumorigenesis
[45]. Despite the use of two different antibodies, we could not find
differences in JARID1B staining between HEp3 LRCs and
NLRCs in situ (Fig. S6A). However, we did find that only ,35%
of HEp3 LRCs were H3K4me3
high (a target of JARID1B) while
,65% of NLRCs were high for this mark that is associated with
transcriptional activation (Fig. 6A). We also tested the levels of
H3K4me3 in HEp3 CD49f
high and CD49f
low cells (Fig. 6B) and
found that similar to NLRCs, 75% of HEp3 CD49f
low cells were
H3K4me3
high. This suggests that the LRC/CD49f
high population
may have a unique chromatin state and perhaps other H3 PTMs
might play a role in determining LRC/CD49f
high to NLRC/
CD49f
low switch and vice versa. We next measured the levels of
H3K27me3 and H3K9me3 marks that are associated with
facultative and constitutive heterochromatin, respectively [46].
These marks have also been found to be modulated in
teratocarcinomas and adult bulk cultures of colon cancer cells
[44]. We found that close to 80% of HEp3 NLRCs/CD49f
low
displayed strong nuclear staining for H3K27me3, while not more
than 20% of HEp3 CD49f
high/LRCs were H3K27me3
high
(Fig. 6A–B). In addition, 80% of NLRCs were H3K9me3
high
(Fig. S6B). DAPI staining was used to conclusively identify the
larger nuclei in HEp3 cells as described [19]. The 20% of
CD49f
high/LRCs HEp3 cells were not entirely negative for these
H3 PTMs, but rather the signals were low and less abundant (Fig.
S6C). Analysis of total H3 expression by immunofluorescence
showed that all cells in both populations were positive for total H3
with equal intensities (Fig. S6D).
In agreement with the reduced H3K27me3 staining, in situ
detection of EZH2, the catalytic subunit of the PRC2 complex
that methylates H3K27 [47], showed that this enzyme was also
low (not absent) in HEp3 LRCs (Fig. 6A). Further, after sorting,
the growing HEp3 LRC progeny restored the levels of EZH2
expression, which is consistent with this enzyme being an E2F
target gene during G1 exit [48] (Fig. 7A).
Because CD49f is required for HEp3 tumor growth (Fig. 5G–
H), we tested the possibility that H3 PTMs might be downstream
of CD49f signaling. Thus, we examined whether the levels of
H3K27me3 and H3K4me3 were modulated upon inhibition of
CD49f (Fig. 7B). We found that inhibition of CD49f caused a
strong overall increase of H3K4me3 and H3K27me3 marks
(Fig. 7C). These results suggest that there is a functional link
between CD49f and H3K4me3 and H3K27me3 marks. However,
we didn’t see any effect on EZH2 expression when we knockdown
CD49f, at as least measured by IF.
Figure 5. CD49f
low/NLRCs can regain their tumorigenic capacity and restore CD49f and ALDH1A1 expression. (A) Tumor latency (left
panel) and tumor take (Right panel) of HEp3 LRCs and NLRCs that were injected in nude mice (10
3 cells/mice). Graphs show mean 6 SD. The numbers
represent the number of animals per group. (B) Quantification of tumor growth by CD49f
highand CD49f
low HEp3 cells upon serial transplantation on
CAMs (1–3 weeks). (C) Tumor latency (left panel) and tumor take (Right panel) of SQ20b LRCs and NLRCs that were injected in NSG mice with matrigel
(10
3 cells/mice). Graphs show mean 6 SD. The numbers represent the number of animals per group. (D) Tumor latency (left) and tumor take (right) of
the progeny of HEp3 LRCs and NLRCs after expansion in culture and injection in nude mice. (E–F) FACS analysis of surface CD49f (E) and ALDH1A1 (F)
expression in the in vitro expanded progeny of LRCs and NLRCs (in vitro progeny) (Left part of the graph) and in tumors from the progeny of the LRCs
and NLRCs expanded in culture (Tumor progeny)( Right part of the graph). (G) Quantification of HEp3 tumor growth after inhibition of CD49f using
siRNA (Lower graph). Inhibition of CD49f expression was measured by FACs (upper left panel) and qPCR (upper right panel) (siC=SiRNA scrambled;
siCD49f=siRNA CD49f). (H) Quantification of HEp3 tumor growth after treatment with a CD49f blocking antibody or an isotype matched IgG. p-
values estimated using Mann-Whitney non-parametric test.
doi:10.1371/journal.pone.0029974.g005
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CD49f
high/LRCs, we found that in patient primary HNSCC
tumors CD49f
high cells displayed almost exclusively a H3K27me3-
low profile (Fig. 6C). We conclude that the H3K27me3 repressive
mark is consistently less abundant in CD49f
high/LRC cells in both
HEp3 and patient HNSCC tumors. This suggests that CD49f
high/
LRC might have a chromatin state poised for active transcription.
The progeny of sorted CD49f
high/LRC expanded in culture
showed that although ERK1/2 activation and H3K27me3 and
H3K9me3 were upregulated, they also retained high CD49f
expression (Fig. 7A, Fig. 5E and Fig. S5B, C, D). The correlative
nature of these studies only allows us to conclude that the behavior
of CD49f
high/P-ERK
low/H3K4/K27me3
low cells may be gov-
erned by epigenetic mechanisms, allowing them to exist in a
dynamic state that dictates tumorigenic capacity.
Discussion
The identification of tumor cell subpopulations in HNSCC
tumors with dynamic tumorigenic potential raises several impor-
tant questions. Our studies suggest that both CD49f
high cells and
LRCs and CD49f
low and NLRC cells are highly dynamic in their
phenotypes allowing the tumor as a whole to remain adaptable to
growth needs and perturbations of the different subpopulations.
Our findings do not completely fit a strict hierarchical model
definition for tumor initiating cells. In fact, our data may better fit
a model where epigenetic and micro-environmental factors
dynamically regulate the phenotypic heterogeneity of different
subpopulations that perhaps dynamically establish a hierarchy
where CD49f
high/LRC cells are at the top of the hierarchy and
CF49f
low/NLRC are the ‘‘differentiated’’ progeny. The dynamic
and reversible occurrence of these defined subpopulations (i.e.
CD49f
high/LRCs) suggests that through this phenotypic hetero-
geneity some tumors may activate a transient and reversible
structure to propel tumor expansion. This has been proposed in
other systems [18,49] and it is evidenced by the capacity of
NLRCs and CD49f
low cells to regain CD49f
high/ALDH
high
expression, regenerate the slow-cycling population and recover
tumorigenic capacity.
Here we provide a molecular description of these subpopula-
tions and reveal a previously unrecognized association between
this dynamic phenotypic heterogeneity and changes in epigenetic
markers. We determined that even the marker-low subpopulation
(NLRCs/CD49f
low) survives the engraftment (10
2–10
3 cells) and is
able to regenerate a marker-high subpopulation (i.e. CD49f
high)
with tumorigenic potential. This is in agreement with other studies
suggesting non-hierarchical and dynamic mechanisms driving iPS
cell reprogramming [50] and the behavior of melanoma tumor cell
sub-populations with reversible tumorigenic phenotypes [45]. Our
results also resemble recent findings showing that transcription
factors that cause epithelial-to-mesenchymal transition (EMT) can
reversibly induce stem cell-like properties in bulk populations of
mammary tumor cells [51].
We believe that the identification of tumor cell subpopulations
with a dynamic regulation of their phenotypic heterogeneity might
have important implications for therapy at least in HNSCC. Even
if marker-defined cells (CD49f
high/ALDH
high) fit the TICs
definition and these tumor cells were to be specifically targeted
and eradicated, the residual microscopic disease (CD49f
low/
ALDH
low) not eliminated by debulking therapies could give origin
to a secondary lesion. Thus, if those cells that escape debulking
strategies may regain a TIC phenotype then eliminating TICs to
irreversibly curtail tumor growth might need of more persistent
strategies to block ‘‘TIC’’ properties [52].
The detection of a subpopulation of CD49f
high/H3K27me3
low
cells in human primary tumors, although descriptive, strengthens
our findings and their relevance to human disease. In human
tumors sections, CD49f
high cells were found as single solitary cells
or as small clusters displaying very strong CD49f signal and both
the frequency and overall staining intensity increased in metastatic
lesions. CD49f is a laminin-5 binding integrin (a6-integrin) that
pairs with b4 and b1 integrin subunits to regulate adhesion
signaling [53,54], but can also signal in a laminin independent
manner [55]. While CD49f was clearly contributing to the
tumorigenic capacity of HEp3 tumor cells and also maintaining
low H3K27me3 levels, how CD49f function is linked to the
transient arrest and subsequent recruitment of these cells for
expansion is not clear. In the bulk of HEp3 tumors a5b1 integrins
are activated by the urokinase receptor (uPAR) to recruit focal
adhesion kinase and EGFR to activate ERK1/2 signaling and
tumor growth [42]. Recent studies suggest that uPAR might
function as a self-renewal regulator and that by pairing with a6-
integrin [56]. Also uPAR expression has been shown by others and
us to follow an oscillating and dynamic pattern of expression [57].
Thus, although it remains unknown, it is possible that reversible
regulation of uPAR and CD49f expression might contribute to the
LRC and NLRC behavior.
The ability of CD49f
low cells and NLRCs to regenerate a
CD49f
high and LRC subpopulations, respectively, suggested that
epigenetic programs might drive the shift between these states. A
similar scenario is observed in embryonic stem (ES) cells that
appear to be poised for active transcription upon receiving specific
stimuli [58,59,60]. Characterization of the CD49f
high and LRCs
revealed that consistent with their transient growth-arrest, they
display low ERK1/2 phosphorylation. However, upon sorting
these cells are immediately able to rapidly proliferate. This
correlated with a burst in ERK1/2 activation and suggests that
these cells are primed to respond to currently unidentified
activating signals for expansion. Analysis of H3 post-translational
modifications showed that 65–80% of CD49f
high/LRCs were
H3K4me3
low, H3K9me3
low and H3K27me3
low (not negative),
with the latter two repressive marks [58,59,60] being more
dramatic in their decrease. This correlated with a similar
distribution for EZH2
low levels in LRCs. These data suggest that
CD49f
high cells and LRCs, which are also CD49f
high, may be held
in a transcription-ready state due to their low levels of
Figure 6. Characterization of ERK signaling and H3 post-translational modifications in TICs. (A) Detection of K27me3, K4me3, EZH2 and
P-ERK1/2 by IF in CFSE-labeled HEp3 cells grown in vivo for 4 days. Representative images, LRCs stained for P-ERK (confocal scanning image – scale
bar=60 mm), K27me3, K4me3 and EZH2 (all standard fluorescence microscopy images – scale bar=80 mm- scale bar inset=60 mm). Contour of LRCs
is delineated with a dashed green line. Arrows=LRCs, arrows with circle=NLRCs. Quantification of marker-positive or negative in LRCS and NLRCs is
shown in the graphs on the right. Y axes show the percentage of cells per tumor. Graphs show mean 6 SD of three independent tumors. (B)
Detection of CD49f, K27me3 and K4me3 in HEp3 cells grown in vivo 6 days. Representative images of CD49f, K27me3 and K4me3, standard
fluorescence microscopy images – scale bar=80 mm- Contour of CD49f
high cells is delineated with a dashed green line. Arrows=CD49f
high, arrows
with circle=CD49f
low. Quantification of marker-positive or negative in CD49f
high and CD49f
low cells is shown on the graphs on the right. Y axes show
the percentage of cells per tumor. Graphs show mean 6 SD of three independent tumors. (C) Detection of K27me3 and CD49f in sections from
human oral primary tumors (PT68880). Scale bar=80 mm. CD49f positive cells are delineated with a dashed red line. Y axes show the percentage of
cells per section. p-values estimated using Mann-Whitney non-parametric test.
doi:10.1371/journal.pone.0029974.g006
Phenotypic Heterogeneity of HNSCC Subpopulations
PLoS ONE | www.plosone.org 12 January 2012 | Volume 7 | Issue 1 | e29974Phenotypic Heterogeneity of HNSCC Subpopulations
PLoS ONE | www.plosone.org 13 January 2012 | Volume 7 | Issue 1 | e29974transcriptionally repressive marks. The NLRC and CD49f
low
subpopulation may have a chromatin organization that reflects a
bivalent state, having to remove K27me3 in order activate the
strong proliferative program observed in LRCs.
Finally, we found similar proportion of JARID1B
high cells in
LRCs and NLRCs. This contrasts recent reports [45] where
JARID1B enriched cells define a slow-cycling melanoma subpop-
ulation. While the use of different methods to identify the slow–
cycling cells might explain this difference, based on our
quantification, there is a small fraction of CFSE+ cells that are
JARID1B
high/H3K4me3
low and H3K27me3
high/H3K9me3
high.
This subpopulation of cells may have a highly repressive
chromatin state, but their fate and function is currently unclear.
As mentioned above, majority of LRCs (,80%) were globally
H3K4me3
low and H3K9/K27me3
low. In contrast, NLRCs dis-
played primarily global repressive (H3K4me3
low and H3K27-
me3
high/H3K9me3
high) or bivalent H3K4me3
high and H3K27-
me3
high/H3K9me3
high) chromatin states. A reversion to a more
permissive state for transcription that might require erasing and/
or writing new H3 PTMs might explain why longer periods are
needed for NLRCs to fully restore their full tumorigenic
potential. In vitro expanded LRCs reactivated ERK1/2 and
upregulated EZH2. However, they retained a ‘‘memory’’ of the
high CD49f levels in culture relative to NLRCs. This suggests
that in LRCs, activation of ERK1/2 signaling and EZH2
expression is not key in regulating CD49f expression. Whether
the above H3 marks are present/absent in the promoter region of
CD49f gene in order to regulate its expression is unknown.
However, the opposite seems to be true, as RNAi to CD49f
cause a global increase in H3K27me3
high cells, suggesting that
regulation of H3 PTMs are downstream from signaling by this
integrin. While mechanistically unclear, such signaling to
chromatin is intriguing and warrants future study. It also remains
unclear what the functional relevance of the slow-cycling
behavior of LRCs shown here and by others is [45]. Analysis
of these subpopulations directly isolated from fresh human
tumors and implanted in NSG mice may provide additional
insight into the relevance of our findings.
Our work identifies a novel mechanism controlling a dynamic
tumorigenicity program in HNSCC experimental tumors models.
Recently it was shown that chromatin remodeling can lead to
adaptive (rather than selective) mechanisms that activate a drug-
tolerant phenotype in cancer cells [61]. Thus, a better under-
standing of the mechanisms regulating the phenotypic heteroge-
neity of tumor cell subpopulations might lead to strategies that
efficiently block the adaptive capacity of tumors to microenviron-
ment- and/or therapy-derived stress conditions.
Materials and Methods
Ethics Statement
All animal studies were approved by Institutional Animal Care
and Use Committees (IACUC) at Mount Sinai School of Medicine
(MSSM). Protocol ID: 08-0728. Start: 06-Apr-2009. Title IACUC
protocol: Plasticity of head and neck cancer initiating cells.
Cell Lines and Xenograft Studies
Tumorigenic (T-HEp3) HEp3 cell were described previously
[26]. Tumor growth on chick embryo CAMs or Balb/c nude mice
has been described previously [41]. All animal experiments were
approved by IACUC (MSSM). When studying the effect of the
function-blocking CD49f antibody in vivo, 1610
6 T-HEp3 cells
were resuspended in 250 ml PBS
++ and incubated with either
Isotype Control Rat IgG or CD49f blocking antibody (10 mg/ml)
for 30 minutes at 37uC. 2610
5 cells were inoculated onto each
CAM. Inoculated cells were treated 24 h post inoculation on the
CAM with the antibodies. Tumors were harvested 4 days later,
minced, digested with collagenase-1A and the number of tumor
cells per nodule was counted. For serial transplantation studies of
HEp3 tumors on CAM, HEp3 tumors were minced and
dissociated with collagenase-IA (see Flow cytometry for additional
details of tumor processing). Tumor cells were counted and a
single cell suspension (8610
4 cells in 50 ml PBS) from each tumor
was reinoculated on CAMs. For RNA interference studies,
transfections of cells with siRNAs targeting the desired sequences
or control scrambled siRNA were performed as previously
described [14]. 24 h after transfection 2610
5 cells were inoculated
on the CAM of 9–10-day-old chicken embryos (Charles River).
One-week post inoculation, the number of tumor cells per nodule
was counted. siRNA knockdown was analyzed either by qPCR or
FACS.
Flow Cytometry
Single-cell suspensions were generated from HEp3, SQ20b or
FaDu xenografts by surgical dissection of tumors from euthanized
nude mice or chicken embryo chorioallantoic membranes (CAMs)
(when indicated for the HEp3s). Tumors were excised, weighed,
minced and enzymatically dissociated into single cell suspensions
by incubation with type 1A collagenase (Sigma - C9891) for
30 min at 37uC. The suspension was then homogenized by
pipeting and the collagenase was inactivated with full serum
media. Subsequently, tumor cells were washed with media for
excess collagenase removal. Tumor cells, recognized by their very
large diameter, were counted with a hemocytometer. Cell viability
was determined by trypan-blue exclusion. Then tumor cells were
Figure 7. Characterization of H3 post-translational modifications upon knockdown of CD49f. (A) Immunoblot of phospho- and total-
ERK1/2, H3K27me3, H3K4me3, H3K9me3 and EZH2 expression in LRCs and NLRCs sorted and expanded in vitro. Total ERK1/2 and Amido black were
used as loading controls. (B) Inhibition of CD49f in HEp3 cells grown in vivo 6 days. Left panels: representative images of CD49f in HEp3 cells
transfected with a scrambled siRNA (siRNA neg) or with a siRNA CD49f. The cells were permeabilized, thus CD49f signal bathes the whole cell but
primarily the cytosol (scale bar=60 mm). Insets, overlay of CD49f and DAPI, showing the CD49f characteristic membrane and cytosolic staining (Scale
bar=40 mM). Upper right graph- quantification of CD49f mean fluorescence intensity (MFI). Lower right graph,-quantification of CD49f expression by
qPCR. (C). Representative images of K4me3 and K27me3 in HEp3 cells transfected with a scrambled siRNA (siRNA neg) or with a siRNA CD49f. Left
panels- standard fluorescence microscopy images – scale bar=80 mm. Quantification of K27me3
high and K4me3
high percentage of cells and mean
fluorescence intensity is shown on the graphs on the right. Graphs show mean 6 SD of three independent tumors. p-values estimated using Mann-
Whitney non-parametric test. (D) Scheme depicting the hypothetical behavior of different populations in HNSCC tumors. Marker high (CD49f
+) and
marker low (CD49f
2) populations within HNSCC tumors can be defined by their corresponding programs characterized by the markers indicated in
the dialogue boxes. CD49f+ can self-renew (path 1) or after transiting through an intermediary state (CD49f
+/2) (Path 2) fully reprogram into CD49f
2
(Path2+3). The intermediary state (CD49f
+/2) is defined by default by the markers in the dialogue box. The MTP model proposed that CD49f
2 cells can
also transit through the intermediary state (Path 4) to then fully reprogram into CD49f
+ (Paths 4+5). Our model also considers that the different paths
are stochastic and tumor cells might transition back and forth between the different states. A remaining open question is what controls the dynamic
plasticity that drives the alternation between these states (question mark).
doi:10.1371/journal.pone.0029974.g007
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ALDH1A1 activity was detected using Aldefluor reagent (Stem
Cell Technologies Inc) according to manufacturer’s instructions.
In some experiments, cells were co-stained with either phycoer-
ythrin-conjugageted CD49f or CD44 antibodies. A list of primary
antibodies is in Methods S1. Samples were analyzed using an LSR
II instrument (Becton Dickinson). Size-based gates were used to
gate out host cells (Chicken or mouse cells), that are smaller than
HEp3 cells. A PE-conjugated Isotype-matched mouse antibody
(R&D Systems) was used as a control. For cell cycle analysis
studies, T-HEp3 cells were stained for ALDH and CD49f as
described above and then cells were stained using Hoechst-33342
(10 mg/ml) for 15 min at 4 C. The cells were washed, centrifuged
and analyzed. For cell sorting experiments, T-HEp3 or SQ20b
cells were harvested either from nude mice or CAMs (in the case of
HEp3), processed as described above and sorted on a FACSAria
Cell Sorter (Becton Dickinson, San Jose, CA). Sorting was
performed at low pressure and using a 120 or 150 mm nozzle to
maximize the viability of sorted cells. In all sorts all doublets and
larger cell aggregates were excluded and only single cells were
sorted. After sorting, an aliquot of sorted cells was always
reanalyzed to check for purity, which was usually .95. Tumor
cells were then counted and resuspended in PBS
++ Viable cells
were inoculated at 10
2,1 0
3,o r1 0
4 cells/50 ml either on CAM
(HEp3 cells) or subcutaneously in mice (nude mice for HEp3 cells
and NGS mice for SQ20b cells). Tumors growth on CAM was
assessed at 7 days. Tumor formation in nude or NGS mice was
evaluated regularly after injection by palpation of injection sites,
and tumor diameters were measured with a caliper.
Label Retention Assay
T-HEp3 cells were incubated with CFSE (20 mM) in PBS for
15 min at 37uC degrees and then were allowed to recover in
complete media for 30 min prior to injection in nude mice or
CAMs. Cells were allowed to grow in vivo for different periods of
time (4–6 days in CAM, 8–12 days in nude mice). Cells from these
tumors were processed as described in the flow cytometry section
above and CFSE+ population (LRC) was analyzed by flow
cytometry and fluorescence microscopy.
Immunohistochemistry
Paraffin embedded sections from human primary tumors and
lymph node metastasis were stained for CD49f expression after
quenching endogenous peroxidase activity. Binding of the primary
antibody was carried out for 30 min at room temperature,
detected by anti-rat secondary (30 min at room temperature)
and revealed using DAB Chromagen.
Immunofluorescence
Cytospins and tumor cells seeded in coverslips were fixed with
4% paraformaldehyde (PFA) in PBS and were permeabilized with
0.1% Triton X-100 (+0.01% SDS in the case of the K27me3,
K4me3, EZH2 and K9me3 staining). Cells were then blocked with
1% PBSA containing 3% normal goat serum (NGS). CD49f
staining did not require a permeabilization step. A list of primary
antibodies is in Methods S1. Secondary antibodies used for
immunofluorescence microscopy were: goat anti-rabbit Alexa
Fluor 568, goat anti-rabbit Alexa Fluor 488 and goat anti-mouse
Alexa Fluor 488 (Invitrogen). For fluorescence analysis of CFSE
stained samples, tumor cells were fixed in 4% PFA and either
seeded in coverslips pretreated with polylysine or used to prepare
cytospins. Cytospins were prepared according to standard
protocols.
Immunoblotting, RT-PCR and Quantitative qPCR
Immunoblotting and RT-PCR were performed as described
previously [14]. Two micrograms of total RNA isolated from
HEp3 cells (Trizol reagent, Invitrogen) were reverse-transcribed
using MMuLV RT (NEB, Ipswich, MA) and then amplified by
standard PCR using Taq DNA polymerase (NEB, Ipswich, MA)
following manufacturer’s instructions. Primers were purchased
from IDT (Coralville, IA). Primer sequences for CD49f are, 59
ATGGAGGAAACCCTGTGGCT 39 (forward) and 59 ACGA-
GAGCTTGGCTCTTGGA 39 (reverse).
Statistical Analysis
For the FACs and immunofluorescence assays the p-values were
estimated using Mann-Whitney non-parametric test with two-
tailed P values,0.05 considered significant. For primary and
secondary tumor formation statistically significant differences were
assessed using one-way ANOVA followed by the Bonferroni
correction with two-tailed P values,0.05 considered significant.
Supporting Information
Figure S1 Expression of ALDH1A1, CD49f, CD44, and
CD71 in HEp3 and SQ20b tumors. (A) FACS quantification
of CD49f expression in 2 HNSSC cell lines kept in culture (SQ20b
and FADU) and in vivo maintained HEp3 cells. (B–C) FACS
analysis of CD44 (B) or CD71 (C) expression in the ALDH
high and
ALDH
low subpopulations. Right - representative histograms, with
numbers indicating the CD44 (B) or CD71 (C) mean fluorescence
intensity (MFI). Left - quantification of CD44 (B) or CD71 (C)
MFI in at least 3 different HEp3 tumors. (D) Image of a cytospin
from a CFSE labeled T-HEp3 tumor grown on the CAM for 4
days. The LRCs (green) are marked by arrows. Scale bar 40 mm.
(E) Detection of LRCs (green) and CD49f positive cells (red) by
immunofluorescence in CFSE-labeled HEp3 cells grown in vivo for
4 days. Scale bar 40 mm. Lower right corner inset: CFSE staining,
the points mark the LRCs. Scale bar: 80 mm. Upper left corner
inset: CD49f staining, the stars mark the CD49f
high cells. Scale
bar: 80 mm. (F) Quantification of LRCs in SQ20b tumors grown
in mice between 7 and 15 days. Left panel. each point represents
the percentage of LRCs per tumor. Middle panel- quantification
of LRCs in SQ20b tumors with different volumes grown in nude
mice. The bigger the tumor is, the more the cells have divided, the
more the CFSE is diluted. Therefore, the bigger tumors have
lower percentage of LRCs. Right panel- Fluorescence photomi-
crograph of a SQ20b LRC (arrow) in a ,1000 mm3 tumor. Scale
bar: 80 mm.
(TIF)
Figure S2 Expression of CD49f in normal epithelium.
Representative images of CD49f staining in benign
adjacent oral squamous epithelium of patient 68880 (A)
and HEp3 tumor (B). Scale bar: 20 mm (left panel) and 40 mm
(right panel) in (A). Scale bar: 60 mm( B). (C) Table showing the
quantification of the mean percent of CD49f positive cells in the
primary tumor and metastasis from each patient. Right panel,
graph representing the mean percentage of CD49f positive cells in
human oral primary tumors (PT) and lymph node metastasis (met).
p-values estimated using Mann-Whitney non-parametric test.
(TIF)
Figure S3 CD49f
High and CD49f
Low cells have similar
adhesive potential to the ECM. (A) Quantification of tumor
growth after 1 week in vivo of sorted ALDH
high and ALDH
low
populations. Dots represent the number of tumor cells per nodule.
p-values estimated using one-way ANOVA followed by the
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significant (B) FACS quantification of CD49f mean fluorescence
intensity in HEp3 tumors disaggregated with either collagenase or
PBS/EDTA. (C) Adhesion to Fibronectin (FN), collagen (CL) and
Laminin (LN) in HEp3, CD49f
high and CD49f
low cells. 25*10‘4
cells per well of 96-well plates, (four wells per experimental point)
were inoculated into wells coated with FN 4 mg/ml, CL 4 mg/ml
or LN 5 mg/ml incubated at 37 C for 30 min, fixed, and stained
with crystal violet (see Methods S1), the dye was extracted, and the
absorbance was measured at 570 nm.
(TIF)
Figure S4 CD49f
low/NLRCs can reprogram and regain
their tumorigenic capacity. (A) Quantification of the number
of population doublings in vivo of LRCs and NLRCs upon serial
transplantation for 5–7 weeks. (B) Detection of CFSE in HEp3
cells before sort (left column), immediately after sort (middle
column) and 5 days after expansion in vitro (right column). Scale
bar 120 mm. (C) Upper table, tumor take for the in vitro expanded
progeny of LRCs and NLRCs on CAM after 1 week in vivo. Lower
panel graph - LRC and NLRC produced tumors after 3 weeks are
able to regenerate again tumors with equal efficiency after 1 week.
(D) Quantification of tumor volume produced by the progeny of
ALDH
high (ALDH+) and ALDH
low (ALDH2) and mixed
populations (ALDH+/2) after in vitro expansion and reinoculation
on CAM. Note that all cells produce tumors of similar size after
being expanded in vitro for several weeks. p-values estimated using
Mann-Whitney non-parametric test.
(TIF)
Figure S5 Stability of CD49f expression and ALDH
activity in the progeny of HEp3 LRCs and NLRCs in
culture. (A) Representative Histograms of purity controls after
sort for NLRCs (right panel) or CD49f
low cells (left panel). (B)
FACS quantification of CD49f (upper and lower left panels) and
ALDH1A1 activity (upper and lower right panels) expression in
the progeny of LRCS and NLRCs expanded in vitro after sorting
(upper panels) from an independent set of tumors from Fig. 5 and
after in vitro expanded cells were allowed to form tumors in vivo
(lower panels). (C) FACS quantification of CD49f (left panel) and
ALDH1A1 (right panel) expression in cells that after sorting were
expanded in vitro for more than 100 generations. (D) Quantifica-
tion of CD49f expression by qPCR in cells that after CD49f
sorting were expanded in vitro for 6 passages (left panel) or that
after CFSE sorter were expanded in vitro for 100 passages (right
panel). (E) The tumor progeny of the NLRCs expanded in culture
were labeled with CFSE (20 mM) and inoculated in vivo. NLRC
after expansion in vitro regain tumorigenic capacity and are able to
generate a LRC population that can be detected by fluorescence
microscopy (left panel). Scale bar: 80 mm. Right panel, quantifi-
cation of the number of CFSE positive cells in 4 days tumors
formed by the progeny of the NLRCs.
(TIF)
Figure S6 Jarid1B and H3K9me3 expression in HEp3
LRCs and NLRCs. (A–B) Detection of CFSE, JARID1B (A) and
H3K9me3 (B) by immunofluorescence in CFSE-labeled HEp3
cells grown in vivo for 4 days. Scale bar: A=40 mm, B=60 mm.
Quantification of positive cells is shown on the right. Graph shows
mean 6 SD of three independent tumors. Y axes represent the
percentage of cells per tumor. p-values estimated using Mann-
Whitney non-parametric test. (C) Detection of CFSE, H3K27me3,
H3K9me3, H3K4me3 by immunofluorescence. Here we used a
short integration time on the digital camera to reveal the H3PTM
high marks (second column). In the third column we used a longer
integration time on the digital camera to show that H3-PTM
marks are present in those cells that appear negative in the second
column. This reveals that it is a degree difference and not a
positive vs. negative difference. Scale bar: 80 mm. (D), Detection of
total H3 levels in LRCs and NLRCs. Note that all cells are positive
for total H3. Scale Bar=80 mm.
(TIF)
Methods S1 Adhesion assays. Adhesion to Fibronectin (FN),
collagen (CL) and Laminin (LN). HEp3, CD49f
high and CD49f
low
cells were inoculated into wells coated with FN 4 mg/ml, CL
4 mg/ml or LN 5 mg/ml, incubated at 37 C for 30 min, fixed,
and stained with crystal violet, the dye was extracted, and the
absorbance was measured at 570 nm. Table of Antibodies.
(DOCX)
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